Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma initially demonstrating near-complete metabolic response to BV-CHEP

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas